세계 안내 렌즈 시장 규모는 예측 기간 동안 연평균 5.5%의 연평균 복합 성장률(CAGR)로 성장하여 2023년 50억 8,000만 달러에서 2031년 77억 9,000만 달러로 성장할 것으로 예상됩니다.
백내장 유병률 증가는 많은 국가에서 경제적, 의료적으로 큰 문제가 되고 있으며, 각국 정부는 백내장 퇴치를 위한 프로그램을 시작하고 있습니다. 백내장은 전 세계 실명 원인 중 1위이며, 대부분의 백내장 환자는 개발도상국에 거주하고 있습니다. 백내장 및 노안, 안검하수와 같은 각막 질환의 관리는 특히 적절한 치료에 대한 접근성이 제한적인 저소득 국가에서 사회경제적 문제로 대두되고 있습니다. 백내장 수술은 효과적임에도 불구하고 세계 인구의 대다수, 특히 경제적 여건과 외과 의사에 대한 접근성이 제한적인 개발도상국에서는 여전히 접근하기 어려운 수술입니다. 그 결과, 상당수의 백내장 환자가 치료되지 않은 채로 남아 백내장 질환의 부담을 가중시키고 있습니다. 눈 건강과 신기술의 장점과 특징에 대한 인식이 시장을 이끄는 주요 요인 중 하나입니다.
세계보건기구(WHO)의 2023년 보고서에 따르면, 전 세계 약 22억 명이 근시 또는 원시 장애를 앓고 있으며, 백내장 환자는 9,400만 명으로 추산됩니다. 정부 지원 증가와 유리한 상환 정책으로 인해 더 많은 환자가 백내장 수술을 받고 있으며, 백내장 수술 장비의 채택이 증가하고 있습니다. 또한, 백내장 수술 지연을 줄이기 위한 노력과 주요 국가에서 안과 의료에 대한 인식이 높아짐에 따라 백내장 수술 장비 시장의 성장을 가속할 것으로 예상됩니다.
백내장 수술 건수 증가
백내장 수술은 전 세계적으로 가장 많이 시행되는 안과 수술 중 하나이며, 많은 투자와 새로운 제품, 서비스 및 기술 혁신의 지속적인 흐름을 끌어들이고 있습니다. 지속적인 발전과 수요 증가로 백내장 수술의 미래는 유망하며, 2030년까지 연평균 백내장 수술 건수가 증가하고 환자들의 평균 연령도 증가할 것으로 예상됩니다. 백내장 수술에 대한 수요 증가는 많은 사람들이 백내장을 앓고 있는 개발도상국에도 영향을 미치고 있으며, 2022년 1월 Scientific Reports에 발표된 연구에 따르면 백내장과 눈꺼풀 처짐이 노인들에게 널리 퍼져 있는 안과적 문제라는 사실이 밝혀졌습니다. 중장년층의 안검하수 유병률은 10% 이상이며, 백내장은 전체 인구의 15%에 영향을 미칩니다.
단초점 안내 렌즈의 비용 효율성이 시장 우위를 주도하고 있습니다.
안내 렌즈 시장에서는 저가형 단초점 렌즈 부문이 가장 큰 점유율을 보이며 시장의 약 55%를 차지하고 있습니다. 이러한 우위는 제품 보험 적용이 더 유리하고 백내장 수술에 단초점 렌즈를 사용하려는 정부의 이니셔티브이 증가함에 따라 발생했습니다.
북미, 안내 렌즈 시장 독주
북미는 세계 안내 렌즈 시장에서 큰 비중을 차지할 것으로 예상됩니다. 이는 시력 관련 질환의 유병률 증가, 미국과 캐나다의 높은 신기술 및 신제품 채택률, 더 나은 의료 시설에 대한 수요 급증에 기인합니다. 이 지역은 백내장 수술기구의 가장 큰 시장이며, 미국이 큰 점유율을 차지할 것으로 예상되며, 2022년 5월 안과 경영의 최신 정보에 따르면, 미국에는 1억 2,800만 명의 노안 환자가 있으며, 이 숫자는 밀레니얼 세대가 40세에 도달하고 노안이 진행됨에 따라 계속 증가하고 있습니다. 이러한 추세는 향후 몇 년동안 안내 렌즈 시장을 주도할 것으로 예상됩니다. 또한, 노화성 백내장 및 선천성 백내장을 포함한 백내장 유병률 증가도 시장 성장에 기여할 것으로 예상됩니다.
세계 안내 렌즈(Intraocular Lens) 시장을 조사했으며, 시장 정의와 개요, 시장 규모 추이 및 예측, 각종 부문별/지역별 상세 분석, 산업 구조, 시장 성장에 영향을 미치는 요인 분석, 사례 연구, 경쟁 구도, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.
Global intraocular lens market is projected to witness a CAGR of 5.5% during the forecast period 2024-2031, growing from USD 5.08 billion in 2023 to USD 7.79 billion in 2031. An intraocular lens (IOL) implant is a synthetic lens placed inside the eye to replace the focusing power of the natural lens, typically as part of cataract surgery. It has been approved as safe and effective by the U.S. Food and Drug Administration since 1981. IOLs are a popular option for improving vision without heavy reliance on contact lenses and glasses.
The increasing prevalence of cataracts presents a significant economic and healthcare challenge in many countries, prompting various governments to initiate programs aimed at eliminating cataracts. Cataracts are the leading cause of blindness worldwide, with most of those affected residing in developing countries. The management of cataracts and even other corneal disorders, such as presbyopia and blepharoptosis, is expected to become a socioeconomic challenge, particularly in low-income nations with limited access to appropriate treatment. Despite the effectiveness of cataract surgery, it remains inaccessible to a large portion of the global population, especially in developing countries where financial means and access to surgeons are limited. As a result, a substantial number of cataract cases remain untreated, contributing to the burden of the disease. This shortcoming is a big reason behind the forthcoming surge in market growth of IOLs. Awareness about eye health and the benefits and features of new technology is one of the primary factors driving the market.
According to a 2023 report by the World Health Organization (WHO), approximately 2.2 billion people globally have near or distant vision impairment, and an estimated 94.0 million people suffer from cataracts. The increasing government support and favorable reimbursement policies have encouraged more patients to undergo cataract surgery, leading to a rise in the adoption of cataract surgery devices. Additionally, initiatives to reduce the backlog of cataract surgeries and the growing awareness of eye care in key countries are expected to drive the market growth for cataract surgery devices.
Increasing Volume of Cataract Surgeries
Cataract surgery is one of the most performed ophthalmic procedures globally. The increasing prevalence of cataracts and associated visual impairments has led to a rise in the number of cataract surgeries performed worldwide. Cataract surgery has the highest volume procedure for the ophthalmic industry, attracting significant investments and a continuous flow of new products, services, and innovations. With continuous advancements and growing demand, the future of cataract surgery is promising. It is projected that by 2030, the average annual volume of cataract surgeries will increase, and the mean age of patients will also increase. The rising demand for cataract surgery is also prevalent in developing countries, where many individuals are affected by cataracts. Various initiatives and organizations are dedicated to addressing the global burden of cataract blindness and increasing access to cataract surgery in developing nations. A study published in Scientific Reports in January 2022 revealed that cataracts and blepharoptosis are prevalent ophthalmic issues among older adults. The prevalence of blepharoptosis in middle-aged to older adults exceeds 10%, while cataracts affect 15% of the population.
Cost Effectiveness of Monofocal IOL is Driving its Dominance in the Market
The intraocular lens market is categorized into monofocal and premium segments. The monofocal segment, which is cheaper, held the largest share of the global intraocular lens market, accounting for around 55% of the market. This dominance is attributed to the products being more favorably reimbursed and the rising number of government initiatives for utilizing monofocal lenses for cataract surgeries. The premium segment, on the other hand, is expected to witness growth prospects, with multifocal IOLs being the most adopted product due to their advantages in treating complex vision problems such as presbyopia or astigmatism. According to an article published in 2023 by the National Institutes of Health (NIH), monofocal lenses are among the most implanted products in the intraocular lens market. The popularity of these products among the general population is due to their favorable reimbursement and has contributed to their growth prospects.
Government Initiatives Acting as Catalyst
The increasing prevalence of cataracts presents a significant economic and healthcare challenge in many countries, prompting various governments to initiate programs aimed at eliminating cataracts. The rise in standalone eye clinics in developed and developing regions is also expected to contribute to the segment's growth. The academic and research institutes segment is expected to attain growth prospects due to active government efforts to train ophthalmologists and the increasing number of doctors opting for fellowship programs to learn about the latest medical technologies. According to a news article published by the Hindu in May 2022, the Government of India proposed a special drive to clear the backlog of cataract surgeries. 7.5 million cataract surgeries were performed in FY2022-FY2023, 9 million cataract surgeries were performed in FY2023-FY2024, and the plan for FY2024-FY2025 is 10.5 million surgeries. The number of cataract surgeries will be done under a special campaign to clear the backlog, and all the Indian states will be given guidance to conduct these procedures.
High Demand for Hydrophobic Acrylic IOLs
Hydrophobic acrylic materials are the leading choice in the IOL industry, holding the largest market share. They are versatile and can be used to manufacture various IOL designs, including monofocal, multifocal, and toric lenses, thereby meeting diverse patient needs. Compared to other IOL materials like silicone, they offer a more cost-effective option while maintaining high quality. Additionally, being water-resistant, they do not readily absorb water, which helps prevent the build-up of protein deposits on the IOL's surface and the associated clouding and vision problems over time. Its high refractive index, low water content, and the ability to be inserted through small incisions make it more widely used in cataract surgeries. The PMMA segment is expected to hold the second-largest market position in the forecast period, particularly in Europe and other regions, due to its cost advantage over acrylic products.
In 2023, Alcon developed a new intraocular lens made from a hydrophobic acrylic named "Clareon PanOptix IOL". Clareon IOL is made from a hydrophobic acrylic with increased water content compared to AcrySof. As per a study conducted in Australia to test the efficacy of the product, majority of eyes that had the Clareon IOL implanted showed Grade 0 glistening (problems that can occur when a patient is undergoing cataract surgery), and 92.9% of the patients had either no posterior capsular opacification (PCO) or PCO that was clinically undetectable. Over the course of the three-year study period, the visual outcomes were excellent and stable.
North America Dominates IOL Market
North America is anticipated to hold a significant share of the global intraocular lens market. This can be attributed to the increasing prevalence of vision-related disorders, high adoption of new technologies and products in the United States and Canada, and a surge in demand for better healthcare facilities. The region is expected to be the largest market for cataract surgery devices, with the United States accounting for a significant share of the market. According to the ophthalmology management's update from May 2022, the United States is home to 128 million presbyopes, a number that continues to grow as millennials reach the age of 40 and develop presbyopia. This trend is expected to drive the intraocular lens market in the coming years. Furthermore, the increasing prevalence of cataract issues, including age-related and congenital cataracts, is projected to contribute to market growth. In 2022, approximately 12 million individuals aged 40 and above in the United States were found to have vision impairment, while 1.2 million Canadians were living with vision loss. These factors are anticipated to fuel the development of the intraocular lens market due to the growing prevalence of eye illnesses and the rising demand for intraocular lenses.
Future Market Scenario (2024 - 2031F)
The future market scenario of the global intraocular lens market is marked by continuous advancements and innovations. Technological advancements are expected to redefine the landscape, by improving the efficacy of cataract surgeries and refractive procedures. The integration of smart technologies, such as adjustable focus lenses and auto-adjusting IOLs, may become more prevalent, offering patients personalized vision correction options. Nanotechnology is expected to play an important role in the development of next-generation IOL materials, promoting improved biocompatibility and optical performance. In January 2022, Aston University announced its partnership with Rayner Intraocular Lenses, the first company in the world to manufacture intraocular lenses (IOLs), to develop the next generation of lenses that give patients a full range of vision without the need for glasses.
Key Players Landscape and Outlook
The global intraocular lens market is characterized by a consolidated structure, with a few major players holding a significant proportion of the market. Alcon Inc. accounts for the highest market share with a strong portfolio, including the ACRYSOF product line, and an established geographical presence. The company has also focused on launching new products and strategic initiatives to increase its market share. Johnson & Johnson Vision Care, Inc. is the second leading player, with a strong market presence in key regions and robust distribution networks. The prominent companies in the intraocular lens market are pursuing acquisitions to strengthen their market presence.
Additionally, they are forming partnerships with non-profit organizations to raise awareness about cataracts and other eye conditions. Furthermore, manufacturers are actively engaged in introducing new products to maintain a robust product portfolio. In January 2023, Bausch + Lomb completed the acquisition of AcuFocus, a privately held company known for its small aperture non-toric extended depth of focus (EDOF) intraocular lens (IOL). This acquisition has provided Bausch + Lomb with access to AcuFocus's innovative IOL technology, including the IC-8 Apthera lens, which received FDA approval in July 2022. Johnson & Johnson Vision Care Inc., announced in December 2022 that the TECNIS Synergy Toric II OptiBlue PC-IOL is now available in India for patients with astigmatism.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.